Strengthening Data Integrity through Prevention and Precision in 2026
In the fast-paced environment of 2026 clinical research, waiting for an audit to find a mistake is a risk no sponsor can afford. Traditional “reactive” oversight—where issues are identified and corrected only after they appear in the data—leads to costly delays, regulatory scrutiny, and compromised patient safety. At BioResearch Partner (BRP), we are shifting the paradigm toward proactive quality oversight in clinical trials. By embedding quality controls directly into our digital infrastructure and daily workflows, BRP identifies potential risks before they become errors, ensuring that our 14 sites maintain the highest global standards for data integrity and participant care.
Our mission in 2026 is to replace the “fix-it-later” culture with a “quality-by-design” framework that guarantees trial success from day one.
The Hidden Costs of Reactive Oversight
Reactive oversight is a relic of the paper-based past. In 2026, BRP advocates for a proactive approach because the traditional model leads to:
- Compromised Data Reliability: When errors are caught weeks after the fact, the “memory” of the data point is lost, leading to messy queries and unreliable results.
- Regulatory Bottlenecks: Reactive sites are often slowed down by internal audits and corrective action plans (CAPAs), delaying the overall study timeline.
- Increased Sponsor Costs: Every day spent fixing a quality issue is a day added to the trial’s duration and a dollar added to the budget.
- Patient Safety Risks: Quality issues in research are often safety issues. Proactive monitoring ensures that protocol deviations affecting participant health are prevented, not just recorded.
- Coordinator Burnout: It is far more taxing for staff to “clean up” old data than it is to enter it correctly the first time using smart, guided systems.
BRP eliminates these risks by utilizing a “Quality-First” digital ecosystem that makes accuracy the path of least resistance.
BRP’s Framework for Proactive Quality Oversight
Our 14 integrated locations in South Florida utilize a tech-forward strategy to ensure proactive quality oversight in clinical trials:
Clinical Trial Site Feasibility Analysis: 10 Metrics Sponsors and CROs Should Evaluate
Clinical Trial Operations | BioResearch Partner Insights
Selecting the right clinical research site can influence nearly every stage of a clinical trial, from startup timelines and patient recruitment to protocol execution and data quality.
Yet one of the biggest challenges facing sponsors and contract research organizations (CROs) is determining whether a research site can realistically deliver on its projected capabilities.
A site may report access to thousands of potential patients, experienced investigators, and advanced medical infrastructure. But how much of that capacity is available for the specific protocol?
That is where clinical trial site feasibility analysis becomes essential.
An effective feasibility assessment goes beyond a questionnaire. It evaluates the evidence behind a site’s recruitment projections, operational readiness, research experience, and ability to execute the protocol.
For sponsors and CROs evaluating clinical research partners, the following ten metrics provide a practical framework for making more informed site-selection decisions.
What Is Clinical Trial Site Feasibility Analysis?
Clinical trial site feasibility analysis is the process of evaluating whether a clinical research site has the patient population, personnel, infrastructure, resources, and operational capacity needed to conduct a proposed study.
The assessment typically takes place before final site selection and activation.
Its purpose is to identify potential barriers before they become costly operational problems.
Why Site Feasibility Matters to Sponsors and CROs
A well-executed clinical trial feasibility assessment can help research teams:
- Identify sites with realistic patient recruitment potential.
- Evaluate investigator experience and availability.
- Understand competing study commitments.
- Assess equipment, facilities, and protocol-specific capabilities.
- Identify potential regulatory and startup delays.
- Develop more reliable enrollment projections.
- Reduce the risk of selecting sites that cannot meet study requirements.
However, feasibility should not be treated as a one-time administrative exercise. The assumptions behind the initial assessment should be reviewed as protocol requirements, site capacity, and recruitment conditions change.

1. Eligible Patient Population
One of the most important metrics in a clinical trial site feasibility analysis is the number of patients who may realistically qualify for the study.
A large patient database does not automatically translate into a large pool of eligible participants.
What Sponsors Should Evaluate
The assessment should distinguish between:
- Patients with the relevant diagnosis.
- Patients who meet major inclusion criteria.
- Patients who are unlikely to meet exclusion criteria.
- Patients who can realistically be contacted.
- Patients who may be interested in participating.
- Patients who are available within the enrollment period.
For example, a research site may have records associated with 2,000 patients with a particular condition. After considering age, treatment history, laboratory requirements, comorbidities, geography, and patient interest, the number of potentially eligible participants may be substantially smaller.
Key takeaway: Evaluate the accessible, protocol-relevant patient population rather than relying on total database size.
2. Historical Patient Recruitment Performance
Recruitment projections are more useful when they are supported by documented performance.
Sponsors and CROs should evaluate whether the site has successfully recruited participants for studies with similar eligibility requirements, therapeutic areas, and visit schedules.
Recruitment Metrics Worth Reviewing
- Number of participants screened.
- Number of participants enrolled.
- Screen failure rate.
- Enrollment per month.
- Time from activation to first participant enrolled.
- Recruitment performance compared with the original projection.
- Participant retention and withdrawal patterns.
Historical results should be interpreted in context. Strong performance in one therapeutic area does not guarantee the same results for a different population or more restrictive protocol.
Why Historical Data Matters
A site that consistently provides realistic forecasts may be more valuable than a site offering ambitious projections without supporting evidence.
The objective is not necessarily to select the site with the highest proposed enrollment number. It is to identify sites whose estimates can be explained, evaluated, and monitored.
3. Principal Investigator Experience and Availability
An experienced principal investigator (PI) is important, but qualifications alone do not establish operational readiness.
A clinical trial site feasibility assessment should evaluate whether the investigator has sufficient time, support, and relevant experience to oversee the proposed study.
Questions Sponsors and CROs Should Ask
- Has the investigator conducted studies in the relevant therapeutic area?
- Does the investigator have experience with comparable protocols?
- How many active studies require the investigator’s attention?
- Is qualified backup or sub-investigator coverage available?
- Is the investigator supported by trained coordinators and research personnel?
- Can the investigator provide appropriate medical oversight throughout the trial?
Investigator availability is especially important for protocols involving complex procedures, frequent safety evaluations, or time-sensitive clinical decisions.
4. Site Staffing and Operational Capacity
Even a well-qualified investigator may struggle to execute a study without adequate operational support.
Sponsors should assess the personnel responsible for day-to-day trial activities.
Essential Staffing Considerations
These may include:
- Clinical research coordinators.
- Regulatory specialists.
- Recruitment and prescreening personnel.
- Laboratory and diagnostic staff.
- Data management support.
- Quality assurance personnel.
- Pharmacy or investigational product personnel, where required.
The assessment should also consider staff training, turnover, competing workloads, and the availability of coverage during absences.
A critical feasibility question is not simply whether a site has staff, but whether the appropriate staff have capacity for the proposed protocol.
5. Clinical Research Infrastructure and Equipment
Research infrastructure should be evaluated against the actual requirements of the study protocol.
Depending on the trial, a site may require specialized diagnostic equipment, laboratory capabilities, secure investigational product storage, infusion facilities, or access to advanced imaging.
Infrastructure Evaluation Checklist
Sponsors and CROs may need to verify:
- Appropriate examination and procedure rooms.
- Laboratory collection and processing capabilities.
- Temperature-controlled storage and monitoring.
- Investigational product handling and accountability procedures.
- Imaging or diagnostic equipment availability.
- Emergency procedures and clinical support.
- Equipment maintenance and calibration records.
- Data systems and secure documentation processes.
The presence of equipment does not necessarily mean that it is available, qualified, or suitable for a specific protocol.
Equipment requirements should be reviewed before activation, including whether any external vendors or additional arrangements are necessary.
6. Regulatory and Startup Readiness
A site may have excellent recruitment potential but still experience significant delays if essential startup activities are not adequately planned.
Regulatory and startup readiness should therefore be part of every clinical trial site feasibility analysis.
Areas to Review
- Essential document readiness.
- Investigator qualifications and training records.
- Institutional Review Board (IRB) submission processes.
- Contract and budget workflows.
- Delegation and training procedures.
- Investigational product and laboratory setup.
- Sponsor-specific system access.
- Site initiation requirements.
Sponsors should distinguish between estimated startup timelines and documented historical performance.
Where possible, feasibility should identify which activities can proceed in parallel and which depend on approvals or external vendors.
7. Competing Clinical Trials and Patient Overlap
A site may be highly experienced in a therapeutic area while simultaneously conducting several studies targeting similar patient populations.
This creates potential competition for eligible participants.
What to Assess
Sponsors should ask whether the site has:
- Other actively recruiting studies in the same indication.
- Overlapping inclusion and exclusion criteria.
- Competing recruitment priorities.
- Shared investigator or coordinator resources.
- Patient populations already committed to other protocols.
This does not mean that sites conducting multiple studies should automatically be excluded.
Rather, the feasibility assessment should determine whether the proposed trial has a realistic opportunity to recruit participants without compromising other study commitments or patient care.
8. Geographic Accessibility and Patient Burden
Patient access can influence recruitment, visit completion, and long-term retention.
A site with strong clinical capabilities may still encounter enrollment challenges if participation requires excessive travel or repeated time away from work and family responsibilities.
Patient Accessibility Factors
Consider:
- Travel distance and transportation options.
- Frequency and duration of study visits.
- Availability of appointment times.
- Language accessibility.
- Parking and public transportation.
- Study-related reimbursement or support where permitted.
- Physical accessibility and participant-specific needs.
These factors are particularly relevant for protocols requiring frequent visits or lengthy follow-up periods.
The Importance of Patient-Centered Feasibility
Feasibility assessments should consider not only whether participants meet clinical eligibility criteria, but whether participation is practical for the population being recruited.
A protocol that appears feasible on paper may be difficult to execute if the patient burden is not realistically assessed.
9. Data Quality and Research Technology
Clinical trial site feasibility analysis should also examine whether the site has appropriate systems and procedures to support accurate, timely, and reliable study documentation.
Technology may improve coordination, but the quality of the underlying workflows remains essential.
Areas Sponsors Should Review
- Electronic data capture experience.
- Electronic source documentation, where applicable.
- Electronic regulatory document management.
- Data entry and query resolution workflows.
- Source documentation practices.
- Access controls and data security.
- Staff training on sponsor-specific systems.
The objective is to determine whether the site’s processes can support protocol requirements and applicable regulatory expectations.
A modern technology platform is valuable only when it is implemented effectively and supported by trained personnel.
10. Enrollment Forecast Accuracy and Risk Management
The final metric brings the feasibility assessment together: the reliability of the site’s projected enrollment and operational performance.
An effective feasibility forecast should be based on clearly documented assumptions.
Building a More Realistic Enrollment Projection
Sponsors and CROs can evaluate the relationship between:
- The potentially relevant patient population.
- Patients likely to be reachable.
- Patients interested in screening.
- Patients expected to satisfy eligibility requirements.
- Participants likely to enroll.
- The time required to complete each stage.
This approach can help identify where recruitment assumptions may be overly optimistic.
Example: A Hypothetical Enrollment Funnel
Suppose a site identifies 500 potentially relevant patients.
After initial review, 250 may appear suitable for outreach. Of those, 100 may express interest in screening. If 60 meet the protocol’s eligibility criteria and 45 ultimately enroll, the projected enrollment is very different from the original database count.
These figures are illustrative, not BRP performance data. Actual conversion rates vary substantially by protocol, population, and recruitment approach.
The goal is to understand how an enrollment estimate was developed, rather than accepting a single projected number without supporting assumptions.
Clinical Trial Site Feasibility Assessment: Quick Checklist
Before selecting a research site, sponsors and CROs should be able to answer the following questions:
| Feasibility area | Key question |
|---|---|
| Patient population | Is the eligible population supported by credible, protocol-relevant evidence? |
| Recruitment history | Has the site demonstrated recruitment performance in comparable studies? |
| Investigator readiness | Does the investigator have relevant experience and sufficient availability? |
| Staffing | Are qualified personnel available to support the study? |
| Infrastructure | Can the site perform the required procedures and assessments? |
| Regulatory readiness | Are startup processes and dependencies clearly understood? |
| Competing studies | Could other protocols affect recruitment or staffing? |
| Patient accessibility | Is participation practical for the target population? |
| Data quality | Are documentation and data management processes appropriate? |
| Forecast reliability | Are enrollment projections supported by transparent assumptions? |
This checklist provides a starting point. Each protocol may require additional therapeutic-area, safety, laboratory, pharmacy, or operational considerations.
How Clinical Research Site Networks Can Support Feasibility
For sponsors and CROs managing multicenter clinical trials, evaluating numerous independent sites can create additional coordination demands.
A clinical research site network or site management organization (SMO) may provide a more centralized approach to certain feasibility and operational activities.
Depending on its structure and capabilities, a network may help coordinate:
- Site capability assessments.
- Patient recruitment planning.
- Investigator and site resource evaluations.
- Regulatory and startup workflows.
- Quality oversight.
- Operational communication across locations.
However, centralized processes do not eliminate the need for site-specific assessments.
Each research location must still be evaluated against the requirements of the protocol.
Why Reliable Feasibility Data Matters
Clinical trial feasibility is not simply about identifying research sites that are interested in conducting a study.
It is about identifying sites that can demonstrate a credible path from protocol requirements to operational execution.
For sponsors and CROs, this means looking beyond optimistic enrollment projections and evaluating the evidence behind each site’s proposed capabilities.
A strong feasibility process combines quantitative metrics with experienced clinical and operational judgment.
It also recognizes that feasibility is dynamic. Patient availability, competing studies, staffing, and operational capacity can change between initial assessment and site activation.
The most useful feasibility data is therefore transparent, current, protocol-specific, and open to reassessment.
Frequently Asked Questions About Clinical Trial Site Feasibility
What is a clinical trial site feasibility assessment?
A clinical trial site feasibility assessment evaluates whether a research site has the patient population, investigators, staff, infrastructure, and operational capacity needed to conduct a particular study.
What are the most important clinical trial feasibility metrics?
Important metrics include eligible patient population, historical recruitment performance, investigator availability, staffing capacity, infrastructure readiness, startup timelines, competing studies, patient accessibility, data quality, and enrollment forecast accuracy.
How is clinical trial site feasibility different from site selection?
Feasibility is the evaluation of a site’s suitability for a specific protocol. Site selection is the broader decision-making process used to identify and choose the sites that will participate in a trial.
Why are patient databases important in feasibility analysis?
Patient databases may help identify potentially relevant participants, but total database size does not establish actual eligibility, interest, availability, or enrollment potential.
Can a site management organization help with clinical trial feasibility?
An SMO may support feasibility by coordinating site information, recruitment planning, operational assessments, and communication across participating research locations. The scope depends on the organization’s capabilities and operating model.
Partner With BioResearch Partner
Better site selection begins with better feasibility information.
BioResearch Partner works within a clinical research network model designed to support research operations, site coordination, patient recruitment, and study execution.
For sponsors and CROs evaluating clinical research sites, understanding site capabilities and recruitment readiness is an important first step toward building a successful study plan.
Explore BioResearch Partner’s clinical research network and connect with our team to discuss your study requirements.
BioResearch Partner — Advancing Clinical Research Through Connected Sites, Operational Coordination, and Patient-Focused Recruitment.
Build Your Study on a Foundation of Quality
In 2026, proactive quality oversight in clinical trials is the only way to ensure success. Partner with BioResearch Partner and experience the peace of mind that comes with precision.
📞 Call: 833-489-4978
🌐 Visit: www.bioresearchpartner.com
📩 Email: info@bioresearchpartner.com
Experience the future of medicine. Partner with BRP and ensure your clinical trial quality is proactive, digital, and future-ready.
